XTAI
4106
Market cap77mUSD
Oct 08, Last price
24.40TWD
1D
0.62%
1Q
3.61%
Jan 2017
-27.92%
IPO
124.88%
Name
Wellell Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 1990 in New Taipei City, Taiwan, Wellell Inc. is a global enterprise active in the medical supplies sector. The company's activities span research and development, manufacturing, and the international distribution (import, export, and sales) of its diverse product portfolio. This includes items for wound care, respiratory therapy devices, assistive welfare equipment, and other electronic medical instruments. Wellell's specific offerings feature pressure relief mattresses and seating, as well as advanced solutions for sleep apnea, such as auto-adjusting pressure systems and their Sleepwell product line. These innovative solutions primarily focus on the prevention of pressure injuries and the management of obstructive sleep apnea.
Key people
Shihe Chen
Senior Assistant General Manager of Finance & Accounting, Corporate Governance Officer · since 2024
Wende Li
General Manager · since 2025
Xiujuan Lin
Deputy General Manager · since 2000
Wenzhe Shi
Deputy General Manager
Yingjie Xu
Senior Deputy General Manager · since 2011
Bikai Li
Chief Strategy Officer · since 2024
Mei-Ju Chen
Director · since 2025
Chunju Han
Chairman of the Board · since 1998
Yongchuan Lee
Chairman of the Board · since 2025
Changqi Liu
Director · since 1998
Director · since 2022
Kuei Hui Cheng
Independent Director · since 2025
Alice Chou
Independent Director · since 2025
Independent Director · since 2025
Hsiung-Ching Lee
Independent Director · since 2019
Tianfa Lin
Independent Director
Independent Director · since 2025
Independent Director
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||